Aggressive Non-hodgkin's Lymphoma Treated at the Institute of Oncology, Istanbul - Treatment, Outcome, and Prognostic Factors
dc.authorid | Eralp, Yesim/0000-0001-9603-4755 | |
dc.authorscopusid | 6701753460 | |
dc.authorscopusid | 8712720400 | |
dc.authorscopusid | 6602597500 | |
dc.authorscopusid | 7005732398 | |
dc.authorscopusid | 6603910613 | |
dc.authorscopusid | 6701530171 | |
dc.authorwosid | Basaran, Mert/Aat-7762-2020 | |
dc.authorwosid | Eralp, Yesim/Aad-7194-2020 | |
dc.contributor.author | Alici, S | |
dc.contributor.author | Bavbek, SE | |
dc.contributor.author | Kaytan, E | |
dc.contributor.author | Basaran, M | |
dc.contributor.author | Eralp, Y | |
dc.contributor.author | Onat, H | |
dc.date.accessioned | 2025-05-10T17:15:09Z | |
dc.date.available | 2025-05-10T17:15:09Z | |
dc.date.issued | 2002 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | Istanbul Univ, Inst Oncol, Istanbul, Turkey | en_US |
dc.description | Eralp, Yesim/0000-0001-9603-4755 | en_US |
dc.description.abstract | In an unselected group of patients with aggressive non-Hodgkin's lymphoma (A-NHL) treated at our institution during a 10-year period (1989-1998), we studied the treatment outcome and influence of possible prognostic factors. Two hundred one patients with A-NHL were analyzed retrospectively with regard to personal, treatment, and disease-specific characteristics. Median age was 55 years (range: 16-87 years) and the male:female ratio was 1.5. During a median follow-up of 26 months, the overall response rate was 74% (complete response 63%, partial response 11%). The 2- and 5-year disease-free survival rates were 49 +/- 3% (mean +/- SEM) and 41 +/- 4%, respectively. In a univariate analysis, the following variables were associated with prognosis in terms of survival: patient age, clinical stage, performance status, B symptoms, erythrocyte sedimentation rate, treatment response, and histologic grade of tumor. In multivariate analyses, patient age, performance status, and treatment response emerged as independent prognostic factors for survival. | en_US |
dc.description.woscitationindex | Science Citation Index Expanded | |
dc.identifier.doi | 10.1097/00000421-200210000-00016 | |
dc.identifier.endpage | 508 | en_US |
dc.identifier.issn | 0277-3732 | |
dc.identifier.issn | 1537-453X | |
dc.identifier.issue | 5 | en_US |
dc.identifier.pmid | 12393993 | |
dc.identifier.scopus | 2-s2.0-0036793760 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 502 | en_US |
dc.identifier.uri | https://doi.org/10.1097/00000421-200210000-00016 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14720/8537 | |
dc.identifier.volume | 25 | en_US |
dc.identifier.wos | WOS:000178546900016 | |
dc.identifier.wosquality | Q3 | |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Non-Hodgkin'S Lymphoma | en_US |
dc.subject | Treatment | en_US |
dc.subject | Prognostic Factors | en_US |
dc.title | Aggressive Non-hodgkin's Lymphoma Treated at the Institute of Oncology, Istanbul - Treatment, Outcome, and Prognostic Factors | en_US |
dc.type | Article | en_US |